Finance

Lists
Why is 688068 down 2,29%?
Dive Deeper
688068:SHA
Beijing Hotgen Biotech Co Ltd
CN¥75,80
-2,29%
(-1,78) 1D
15 Okt., 09:25:02 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 688068...
Open
CN¥75,80
High
CN¥75,80
Low
CN¥75,80
Mkt. cap
7,15 mjd
Avg. vol.
2,31 m
Volume
5,84 k
52-wk high
CN¥214,78
52-wk low
CN¥73,44
EPS
-CN¥3,00
No. of employees
1 k
Open
CN¥75,80
High
CN¥75,80
Low
CN¥75,80
Mkt. cap
7,15 mjd
Avg. vol.
2,31 m
Volume
5,84 k
52-wk high
CN¥214,78
52-wk low
CN¥73,44
EPS
-CN¥3,00
No. of employees
1 k
News stories
From web sources and news partners
Profile
Hotgen Biotech, often simply referred to as Hotgen, is a Chinese biological technology company founded in 2005. It focuses on the manufacture of in-vitro diagnostic instruments and reagents. In September 2019, the company was listed on the Shanghai Stock Exchange. During the novel coronavirus pandemic, it specialized in making 2019-nCoV antigen diagnostic products, which obtained EU CE certification. Hotgen was formerly a constituent of the STAR 50 Index. Headquartered in Beijing, it also established presences in foreign markets, such as the United Kingdom, France, and Germany. The net profit of the company in 2021 exceeded 2.3 billion yuan, an increase of more than sixteen times from the previous year. In 2022, its RAT kits were distributed free of charge by the Hong Kong Government to the public. In November 2023, it attended the MEDICA Trade Fair in Düsseldorf. Wikipedia
About Beijing Hotgen Biotech Co Ltd
CEO-
Employees1,04 k
Founded23 Jun. 2005
Headquarters-
SectorHealth care
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
105,80 m
95,17 m
116,03 m
151,72 m
Cost of goods sold
49,91 m
40,31 m
55,11 m
36,50 m
Cost of revenue
49,91 m
40,31 m
55,11 m
36,50 m
Research and development expenses
19,65 m
94,81 m
49,10 m
46,03 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
83,78 m
99,31 m
97,60 m
127,34 m
Operating expense
98,59 m
204,82 m
143,51 m
186,68 m
Total operating expenses
148,50 m
245,13 m
198,62 m
223,17 m
Operating income
-42,70 m
-149,96 m
-82,59 m
-71,46 m
Other non operating income
-273,76 k
2,19 m
-2,39 m
2,09 m
EBT including unusual items
-20,92 m
-155,14 m
-82,67 m
-76,94 m
EBT excluding unusual items
-28,82 m
-122,01 m
-69,59 m
-76,99 m
Income tax expense
4,59 m
-6,98 m
-5,78 k
-796,34 k
Effective tax rate
-21,96%
4,50%
0,01%
1,03%
Other operating expenses
-5,37 m
6,99 m
-2,96 m
3,17 m
Net income
-24,96 m
-107,09 m
-68,06 m
-58,07 m
Net profit margin
-23,59%
-112,52%
-58,66%
-38,27%
Earnings per share
-
-
-
-
Interest and investment income
14,98 m
35,99 m
15,44 m
3,94 m
Interest expense
-289,66 k
-7,96 m
-46,88 k
-7,63 m
Net interest expenses
14,69 m
28,03 m
15,39 m
-3,69 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-21,62 m
-129,90 m
-62,53 m
-53,46 m
Gain or loss from assets sale
601,43 k
-579,43 k
-
6,83 k
AI content may include mistakes. Learn more
Google-programme